(Pancreatic Cancer) Is Niraparib + Ipilimumab Effective?
Medical Supporter — إشعار معلوماتي
هذه المقالة ملخص لمعلومات طبية دولية وليست نصيحة طبية، ولا يمكن أن تحل محل تشخيص طبيبك المعالج أو خطة العلاج. المعلومات المعروضة مجمّعة من منشورات عامة وبيانات رسمية لكبرى المؤسسات الطبية اليابانية؛ وتختلف ملاءمة ونتائج أي علاج من مريض لآخر ويجب أن يقيّمها طبيب مؤهل لكل حالة على حدة.
On July 7, 2022, Kim A. Reiss et al. from Abramson Cancer Center published in the medical journal The Lancet Oncology the "Efficacy and Safety Results of Niraparib + Opdivo and Niraparib + Ipilimumab as Maintenance Therapy in Pancreatic Cancer Patients Who Had Not Progressed After at Least 16 Weeks of Platinum-Based Chemotherapy, from a Phase 1b/2 Clinical Trial."
This Phase 1b/2 clinical trial randomized pancreatic cancer patients who had received platinum-based chemotherapy for at least 16 weeks without disease progression (N=91) in a 1:1 ratio to: the Niraparib (200 mg once daily) + Opdivo (240 mg every two weeks, later changed to 480 mg every four weeks) group (N=46) or the Niraparib (200 mg once daily) + Ipilimumab (3 mg/kg every two weeks) group (N=45). The primary endpoints were safety and 6-month progression-free survival rate.
At a median follow-up of 23.0 months, the primary endpoint 6-month progression-free survival rates were: Niraparib + Opdivo group 20.6% / Niraparib + Ipilimumab group 59.6%.
In terms of safety, Grade 3 or higher adverse event rates were: Niraparib + Opdivo group 22% (N=10/46) / Niraparib + Ipilimumab group (N=23/45). Adverse events in the Niraparib + Opdivo group included hypertension 8%, anemia 4%, and thrombocytopenia 4%. In the Niraparib + Ipilimumab group: fatigue 14%, anemia 11%, and hypertension 9%.
Based on the Phase 1b/2 clinical trial results, Kim A. Reiss et al. stated: "In pancreatic cancer patients who had not progressed after at least 16 weeks of platinum-based chemotherapy, maintenance therapy with Niraparib + Ipilimumab improved the 6-month progression-free survival rate, while maintenance therapy with Niraparib + Opdivo showed a lesser improvement in the 6-month progression-free survival rate."
Source: https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(22)00369-2/fulltext
Medical Supporter was formerly certified as an international medical visa guarantor by Japan's Ministry of Foreign Affairs and the Ministry of Economy, Trade and Industry (B-066).
هل تفكر في تلقّي العلاج في اليابان؟ هل تحتاج إلى معلومات ومساعدة؟
نساعدك في تنظيم المعلومات اللازمة للسفر الطبي إلى اليابان، والتواصل مع المؤسسات الطبية اليابانية، وترتيب استشارة رأي ثانٍ.الاستشارة الأولى مجانية؛ سيساعدك المستشار على توضيح الخطوات التالية.
Figure 1
Figure 2
Figure 3
Figure 4